Clinical trials: Face
Peripheral Nerve Facial Nerve Paralysis, Facial Nerve Diseases
Study of a New Technique to Improve the Symptoms of Orofacial Discomfort in Patients With Peripheral Facial Paralysis
The purpose of this study was to evaluate the effects of Neuro Occlusal Rehabilitation (RNO) in patients with peripheral facial palsy (PFP) disease, noting the decrease in symptoms of masticatory dysfunction.
- Conditions
- Peripheral Nerve Facial Nerve Paralysis, Facial Nerve Diseases, Orofacial Pain
- Trial name
- NCT01327157
- Testing
- occlusal adjustment., Visual analog scale.
- Where
- Brazil
- Volunteers
- 14 people
- Sponsor
- Federal University of São Paulo
Facial Aesthetic Treatment
Safety and Efficacy of Treatment With Azzalure, Restylane/Emervel Filler and Restylane Skinbooster
The efficacy and safety, as well as subject satisfaction will be evaluated after single treatment with Azzalure alone or Restylane/Emervel filler alone followed by repeated combined treatment with Azzalure, Restylane/Emervel…
- Trial name
- NCT02297503
- Testing
- Azzalure, Restylane/Emervel filler, Restylane Skinbooster
- Where
- 3 sites in France, Sweden
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Acute Pain
Intranasal Ketorolac for Postsurgical Pain in Dental Implant Patients
The surgical placement of dental implants is presently a common procedure performed by oral surgeons, periodontists, and general dentists.
- Trial name
- NCT01490931
- Testing
- Ketorolac Nasal Spray
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Hersh, Elliot V., DMD, MS, PhD
Actinic Keratosis
A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
This Phase III study is designed to assess the efficacy and safety of PEP005 Gel, 0.015% when applied to an area of skin containing 4-8 AK lesions on the face or scalp.
- Trial name
- NCT00915551
- Testing
- PEP005 (Ingenol Mebutate) gel, 0.015%, Vehicle Gel
- Where
- 21 sites in United States, Australia
- Volunteers
- 278 people
- Sponsor
- Peplin
Facial Pain, Rhinosinusitis
Erenumab for Idiosyncratic Facial Pain
This is a phase IV randomized, double-blinded, placebo-controlled study to evaluate the efficacy of Erenumab in subjects with midfacial pain or pressure, without clinical or radiographic evidence of sinusitis.
- Trial name
- NCT04249427
- Testing
- Erenumab Prefilled Syringe
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- David Jang, M.D.
Skin Aging
Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face
The purpose of this study is to determinate whether Xeomin® (Botulinum toxin Type A) is safe, effective and tolerable in woman aged 30 to 50 years old for treatment of mild, moderate or severe expression lines (wrinkles) in the…
- Trial name
- XEO-001/07 (NCT00986570)
- Testing
- Botulinum Toxin A
- Where
- Brazil
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Biolab Sanus Farmaceutica
Acne Vulgaris
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
CB-03-01 is being developed for the topical treatment of acne vulgaris, an androgen-dependent skin disorder. The purpose of this study is to compare the safety and efficacy of multiple concentrations of CB-03-01 to vehicle in the…
- Trial name
- NCT01631474
- Testing
- CB-03-01, Vehicle
- Where
- 13 sites in United States
- Volunteers
- 363 people
- Sponsor
- Intrepid Therapeutics, Inc.
Acne Vulgaris
U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™
One of the main success factors in acne therapy is user compliance with treatment, product cost, availability and ease of use. Poor compliance may translate into decreased efficacy (either not improving symptoms well enough or…
- Trial name
- NCT01706250
- Testing
- MAXCLARITY II (2.5% BPO) Foam Cleanser, MAXCLARITY II (2.5% BPO) Foam Treatment, MAXCLARITY II (0.5% Salicylic Acid) Toner Foam
- Volunteers
- 20 people
- Sponsor
- Stiefel, a GSK Company
Obstructive Sleep Apnea
A Phase II Pilot Study of the Trillium Full Face Mask
This will be a single-center, open-label randomized crossover design pilot study to evaluate the clinical safety, clinical performance, and clinical benefit of the Trillium full face mask
- Trial name
- NCT06932055
- Testing
- Trillium Full Face Mask, AirFit F20
- Volunteers
- 40 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Maxillofacial Injuries, Maxillofacial Prosthesis Implantation
A Clinical Trial of Locally Made Titanium Miniplate and Screw in Maxillofacial Fractures Management
The study is a blind randomized clinical study on patients with midface maxillofacial fractures coming to Cipto Mangunkusumo Hospital.
- Conditions
- Maxillofacial Injuries, Maxillofacial Prosthesis Implantation, Fracture Fixation, Internal
- Trial name
- NCT04279925
- Testing
- ORIF (Open reduction internal fixation): locally-made miniplate and screw, ORIF: Imported miniplate and screw
- Where
- Indonesia
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Acute Respiratory Insufficiency
Evaluation Of The Total Face Mask For Emergency Application In Acute Respiratory Failure
The purpose of this study is to compare the Total Face Mask™ (Respironics, Inc., Pittsburgh, PA) (covering whole face) and the standard oronasal facemask (covering nose and mouth) for the emergency treatment of patients with…
- Trial name
- NCT00686257
- Testing
- Total face mask (interface for NPPV), Comfort full or RT040 oronasal mask (interface for NPPV)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Tufts Medical Center
Cushing's Syndrome
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.
- Trial name
- SEISMIC (NCT00569582)
- Testing
- mifepristone
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Corcept Therapeutics
Nasolabial Fold Correction
Multicenter Double-Blind Randomized Split-Face Study to Evaluate Revanesse® Ultra vs Restylane® for Correction of NLF
A randomized, multicenter, double blind, split-face study in subjects seeking NLF correction. Subjects were treated with Revanesse Ultra in the NLF on one side of the face and Restylane in the NLF on the other side of the face.
- Trial name
- NCT02987205
- Testing
- Revanesse Ultra, Restylane
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Prollenium Medical Technologies Inc.
Sleep Apnea Syndromes
Amara View Benchmark Study
This randomized crossover, benchmark clinical trial aims to compare the Philips Amara View and ResMed AirFit F40 minimal contact full face masks on patient preference of mask attributes and usage parameters.
- Trial name
- NCT06535932
- Testing
- Amara View Minimal Contact Full Face Mask, F40 Minimal Contact Full Face Mask
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Eustachian Tube Dysfunction, Facial Pain
SinuSonic for ETD and Facial Pain: Acoustic Vibration + Oscillating Expiratory Pressure
This study was originally designed with three aims: (1) healthy controls to assess nasal nitric oxide, (2) adults with Eustachian Tube Dysfunction (ETD), and (3) adults with facial pain/pressure.
- Trial name
- NCT04404036
- Testing
- SinuSonic Device
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
Actinic Keratoses
Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses
The purpose of this study is to determine if use of topical imiquimod cream after cryotherapy of actinic keratoses reduces the total number of lesions (those treated with cryotherapy and new ones) at follow-up.
- Trial name
- NCT00774787
- Testing
- imiquimod 5% cream
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Rigel Dermatology
Surgical Complication, Paresthesia
Trial of Bilateral Sagittal Split Osteotomy Induced Paresthesia Using Ultrasonic vs. Reciprocating Saw Instrumentation
The aim of this prospective study is to analyze the postoperative paresthesias experienced in patients who undergo bilateral sagittal split osteotomies (BSSO) using an ultrasonic saw, versus a reciprocating saw.
- Conditions
- Surgical Complication, Paresthesia, Fracture, Nerve Injury
- Trial name
- NCT05205616
- Testing
- Sonopet ultrasonic saw, Reciprocating saw
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Age-related Volume Deficit in the Mid-face
The Volumizing Effect of Juvéderm VOLUMA® in the Mid-Face
This is a prospective, observational study of the volumizing effect of aesthetic use of Juvéderm VOLUMA® with lidocaine in the mid-face area.
- Trial name
- NCT01559064
- Testing
- Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)
- Where
- 4 sites in Belgium, Germany and 2 more
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Allergan Medical
Angiofibroma of Face, Tuberous Sclerosis
Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex
The objective of this study is to evaluate the safety and efficacy of sirolimus (0.2% and 0.4% formulations) and its vehicle when applied topically once daily for 12 weeks for the treatment of cutaneous angiofibromas in pediatric…
- Trial name
- NCT03363763
- Testing
- Sirolimus 0.2%, Sirolimus 0.4%
- Where
- 8 sites in United States, China
- Volunteers
- 24 people
- Sponsor
- Aucta Pharmaceuticals, Inc
HIV Infections
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
This is a 90-day medication adherence study testing the HiDO is an automated AI-driven direct observation medication adherence platform, which is a 510K-exempt, Class I medical device with 24 people with HIV/AIDS, ages 18 to 55…
- Trial name
- NCT05454514
- Testing
- HiDO medication adherence platform, Automated Medication Platform with Video Observation, Time on Task
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Charles Gellman